array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Becton, Dickinson and Company" ["slug"]=> string(37) "4601d-us-becton-dickinson-and-company" ["logo"]=> NULL ["description"]=> NULL ["address_street"]=> string(11) "1 Becton Dr" ["address_place"]=> string(14) "Franklin Lakes" ["address_region"]=> string(10) "New Jersey" ["founding_date"]=> string(10) "1897-02-28" ["website_domain"]=> string(6) "bd.com" ["website_url"]=> string(18) "https://www.bd.com" ["industry_codes"]=> array(2) { [0]=> string(46) "Surgical and Medical Instruments and Apparatus" [1]=> string(60) "Orthopedic, Prosthetic, and Surgical Appliances and Supplies" } ["employee_count"]=> int(1500) ["article_count"]=> int(417) } ["articles"]=> array(4) { [0]=> array(7) { ["title_en"]=> string(109) "With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns" ["snippet_en"]=> string(121) "Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to..." ["url"]=> string(84) "https://au.news.yahoo.com/90-institutional-ownership-becton-dickinson-130022702.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f5b29773-3cca-4d1f-9924-f45a2e206e09" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-09-29" ["categories"]=> array(5) { [0]=> string(12) "Stock Market" [1]=> string(21) "Competitive Behaviour" [2]=> string(15) "Market Movement" [3]=> string(18) "General Investment" [4]=> string(24) "Stock Research & Ratings" } } [1]=> array(7) { ["title_en"]=> string(85) "Raymond James Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $304.00" ["snippet_en"]=> string(297) "Becton, Dickinson and Company (NYSE:BDX – Free Report) had its price target reduced by Raymond James from $305.00 to $304.00 in a research report report published on Friday morning, Benzinga reports. Raymond James currently has an outperform rating on the medical instruments supplier’s stock." ["url"]=> string(124) "http://www.defenseworld.net/2023/08/08/raymond-james-lowers-becton-dickinson-and-company-nysebdx-price-target-to-304-00.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b220e2fa-d3cf-42e3-a28b-fe58c2d123b4" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-08-08" ["categories"]=> array(4) { [0]=> string(21) "Competitive Behaviour" [1]=> string(24) "Stock Research & Ratings" [2]=> string(12) "Stock Market" [3]=> string(17) "Academic Research" } } [2]=> array(7) { ["title_en"]=> string(109) "With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns" ["snippet_en"]=> string(121) "Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to..." ["url"]=> string(86) "https://uk.movies.yahoo.com/90-institutional-ownership-becton-dickinson-120120512.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e737a4bc-ab81-45be-8a45-de98a0746079" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-07-16" ["categories"]=> array(2) { [0]=> string(21) "Competitive Behaviour" [1]=> string(12) "Stock Market" } } [3]=> array(7) { ["title_en"]=> string(84) "Medtech firm BD dives into growing pharmacy automation market with $1.5B acquisition" ["snippet_en"]=> string(297) "Hungry for a slice of the budding pharmacy automation market, medical technology firm Becton, Dickinson and Company announced today plans to acquire Parata Systems for more than $1.5 billion. | BD 's acquisition of Parata Systems gives the medtech firm access to a$ 600 million pharmacy automation" ["url"]=> string(117) "https://www.fiercehealthcare.com/health-tech/medtech-firm-bd-dives-growing-pharmacy-automation-market-15b-acquisition" ["image_url"]=> string(78) "https://images.businessradar.com/articles/aa189ca0-3ecf-41c1-a61f-b203278dc070" ["source"]=> string(20) "fiercehealthcare.com" ["publication_date"]=> string(10) "2022-06-06" ["categories"]=> array(4) { [0]=> string(25) "Business Model Resilience" [1]=> string(21) "Competitive Behaviour" [2]=> string(18) "Expansion & Growth" [3]=> string(11) "Acquisition" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(44) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(26) } [2]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(20) } [3]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(20) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(20) } [5]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(20) } [6]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(17) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(15) } [8]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(15) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(13) } [11]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(12) } [12]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(12) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(11) } [14]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(9) } [15]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(8) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(8) } [17]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(8) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(7) } [19]=> array(2) { ["name"]=> string(14) "Product Recall" ["count"]=> int(6) } [20]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(6) } [21]=> array(2) { ["name"]=> string(25) "Leadership and Governance" ["count"]=> int(5) } [22]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(5) } [23]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(5) } [24]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(5) } [25]=> array(2) { ["name"]=> string(21) "Cultural developments" ["count"]=> int(4) } [26]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(4) } [27]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(4) } [28]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(4) } [29]=> array(2) { ["name"]=> string(19) "Green & Responsible" ["count"]=> int(4) } } } 4601d-us-becton-dickinson-and-company

Becton, Dickinson and Company

Location

New Jersey

Founded

1897-02-28

Website

https://www.bd.com

Articles

417 Articles

Category

Surgical and Medical Instruments and Apparatus

Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Description

Articles

With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns

2023-09-29 (yahoo.com)

With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to...

Read more
Raymond James Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $304.00

2023-08-08 (defenseworld.net)

Raymond James Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $304.00

Becton, Dickinson and Company (NYSE:BDX – Free Report) had its price target reduced by Raymond James from $305.00 to $304.00 in a research report report published on Friday morning, Benzinga reports. Raymond James currently has an outperform rating on the medical instruments supplier’s stock.

Read more
With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns

2023-07-16 (yahoo.com)

With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to...

Read more
Medtech firm BD dives into growing pharmacy automation market with $1.5B acquisition

2022-06-06 (fiercehealthcare.com)

Medtech firm BD dives into growing pharmacy automation market with $1.5B acquisition

Hungry for a slice of the budding pharmacy automation market, medical technology firm Becton, Dickinson and Company announced today plans to acquire Parata Systems for more than $1.5 billion. | BD 's acquisition of Parata Systems gives the medtech firm access to a$ 600 million pharmacy automation

Read more

Newsletter subscription